Altamira Therapeutics Ltd. · OTC:CYTOF

Altamira Therapeutics — Auris Medical Holding — Investor Presentation (October 2019)

37 slides from Altamira Therapeutics's investor presentation, Oct 23, 2019

  1. Slide 1: Corporate Presentation October 2019

    Slide 1: Corporate Presentation October 2019

    Corporate Presentation October 2019 NASDAQ: EARS Contact: investors@aurismedical.com Innovative Treatments in Neurotology and CNS Disorders

  2. Slide 2: Forward-looking Statements

    Slide 2: Forward-looking Statements

    1 Forward - looking Statements This presentation and the accompanying oral commentary may contain statements may contain statements that constitute “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. F

  3. Slide 3: Dedicated to Targeted Drug Delivery

    Slide 3: Dedicated to Targeted Drug Delivery

    2 Dedicated to Targeted Drug Delivery • Founded in 2003 • Targeted drug delivery • Pioneer role in neurotology : vertigo, hearing loss, tinnitus • Expanding into CNS • Headquartered in Basel, Switzerland • IPO in August 2014 on Nasdaq (EARS) Auris Medical develops novel pharmaceutical products for u

  4. Slide 4: Our Core Team

    Slide 4: Our Core Team

    3 Our Core Team www.aurismedical.com | NASDAQ: EARS Thomas Meyer, PhD Founder, Chairman and CEO • CEO and BoD member Disetronic • Instrumental in Disetronic’s IPO and managing >20% sales CAGR over many years Elmar Schärli, CPA Chief Financial Officer • ~ 30 years private and public company finance a

  5. Slide 5: Project Pipeline

    Slide 5: Project Pipeline

    Project Pipeline 4 * Dates of key milestones are indicative and subject to change Product Indication Preclin . Phase 1 Phase 2 Phase 3 Next Key Milestones AM - 125 Betahistine Vertigo Phase 2 POC trial interim analysis (Q1 2020) AM - 201 Betahistine Antipsychotic - induced weight gain Phase 1b compl

  6. Slide 6: Intranasal Betahistine

    Slide 6: Intranasal Betahistine

    Intranasal Betahistine (Auris Medical Cochlear therapies 5

  7. Slide 7: Betahistine Targets the Histaminergic System

    Slide 7: Betahistine Targets the Histaminergic System

    Betahistine Targets the Histaminergic System 6 Key role in regulation of wide range of behavioral and physiological functions, including appetite, drinking, sleep, wakefulness, learning, attention and memory. Betahistine is a structural analog of histamine and acts as: • H 1 receptor agonist • H 3 r

  8. Slide 8: How Betahistine is Used Today

    Slide 8: How Betahistine is Used Today

    7 How Betahistine i s Used Today • Widely used around the world for the treatment of vestibular disorders (Meniere’s disease, vertigo) • Oral intake, approved daily dose = 48 mg • Recognized as a safe drug and approved in 115 countries (U.S. being notable exception) Evidence for efficacy is mixed ,

  9. Slide 9: Superior Bioavailability of Intranasal Dosing

    Slide 9: Superior Bioavailability of Intranasal Dosing

    Superior Bioavailability of Intranasal Dosing 8 Data from Phase 1 Study www.aurismedical.com | NASDAQ: EARS 0 5 10 15 20 25 0.0 0.5 1.0 1.5 2.0 2.5 3.0 Median betahistine plasma concentration (ng/mL) Time post - dose (h) Oral 48 mg 5 mg 10 mg 20 mg 40 mg • Relative bioavailability of intranasal beta

  10. Slide 10: AM-125 for Vertigo Treatment

    Slide 10: AM-125 for Vertigo Treatment

    AM-125 for Vertigo Treatment (@ Auris Medica

  11. Slide 11: Overview on Vertigo

    Slide 11: Overview on Vertigo

    10 Overview on Vertigo www.aurismedical.com | NASDAQ: EARS THE PROBLEM • Spinning or wheeling sensation • Disorientation, imbalance , falls, nausea, vomiting, anxiety POTENTIAL CAUSES • Functional: Meniere’s disease, labyrinthitis • Neurosensory: vestibular neuritis • Mechanical: benign paroxysmal p

  12. Slide 12: Positioning of Betahistine

    Slide 12: Positioning of Betahistine

    • Antihistaminergic drugs : diphenhydramine / dimenhydrinate , meclizine … • Anticholinergic drugs : e.g . scopolamine (U.S.) • GABA agonist drugs : benzodiazepines ( e.g . diazepam ) Peripheral level – inner ear hair cells Central level – vestibular nucleus neurons Positioning of Betahistine Soto &

  13. Slide 13: Role of Betahistine in Vertigo Treatment

    Slide 13: Role of Betahistine in Vertigo Treatment

    12 Role of Betahistine in Vertigo Treatment 0% 10% 20% 30% 40% 50% 60% 70% Betahistine Piracetam Ginkgo biloba Other vertigo therapy Diuretics Benzodiazepines Antihistamines Neuroleptics Calcium antagonists Homeopathics 4,294 vertigo patients enrolled in REVERT registry at 618 international centers

  14. Slide 14: Higher Bioavailability Translates Into Better Efficacy

    Slide 14: Higher Bioavailability Translates Into Better Efficacy

    13 Higher Bioavailability Translates Into Better Efficacy Tighilet et al. (2018). Betahistine treatment in a cat model of vestibular pathology: pharmacokinetic and pharmacodynamic approaches. Front Neurol. 11(9): 431. Cats undergoing unilateral section of vestibular nerve → surgery - induced acute v

  15. Slide 15: AM-125 Intranasal Betahistine for Acute Vertigo

    Slide 15: AM-125 Intranasal Betahistine for Acute Vertigo

    14 AM - 125 Intranasal Betahistine for Acute Vertigo Target Indication: treatment of acute vertigo • 3 times daily, metered dose spray Objective: achieve efficacy superior to oral betahistine based on improved bioavailability Clinical Milestones • First Phase 1 trial in 40 healthy volunteers complet

  16. Slide 16: Phase 2 TRAVERS Trial

    Slide 16: Phase 2 TRAVERS Trial

    15 Phase 2 TRAVERS Trial • Acute vertigo after vestibular schwannoma resection » “Clean” one - sided loss of peripheral vestibular input » Patients unable to stand or walk post - surgery • Objective primary efficacy outcomes » T ime standing on foam » Tandem Romberg test • 138 patients » Part A: dos

  17. Slide 17: Attractive Market Potential in Vertigo

    Slide 17: Attractive Market Potential in Vertigo

    16 Attractive Market Potential in Vertigo • Current worldwide annual sales of oral betahistine : ~$ 450 million (IMS, manufacturer prices ) » Branded generics ( Serc , Betaserc ) and full generics » Does not include U.S. sales – compounding pharmacies on small scale • With AM - 125 , we aim to: » Ga

  18. Slide 18: AM-125 Advisory Board

    Slide 18: AM-125 Advisory Board

    17 AM - 125 Advisory Board Elias Michaelides , MD Associate Professor of Surgery, Otolaryngology Director of the Hearing and Balance Program Yale School of Medicine Hinrich Staecker , MD, PhD David and Mary Zamierowsky Professor Director Division Otology/ Neurotology Departments of Otolaryngology, H

  19. Slide 19: AM-201 for Mental Health Supportive Care

    Slide 19: AM-201 for Mental Health Supportive Care

    AM-201 for Mental Health Supportive Care (@ Auris Medica

  20. Slide 20: Significant Need in Mental Health Supportive Care

    Slide 20: Significant Need in Mental Health Supportive Care

    19 Significant Need in Mental Health Supportive Care Drugs for schizophrenia and bipolar disorder have major side effects associated with weight gain, metabolic problems and drowsiness Potential Major Side Effects Include • Impaired glucose tolerance • New - onset diabetes • Hyperlipidemia • Cardiov

  21. Slide 21: The Magnitude of the Problem

    Slide 21: The Magnitude of the Problem

    The Magnitude of the Problem 20 • 64 %, 32%, and 12% of schizophrenia and bipolar disorder patients gained ≥7%, ≥15%, and ≥25%, of their baseline body weight after ≥48 weeks on olanzapine 3 • Incidence of clinically relevant weight gain over 3 years in patients with a first psychotic episode 4 • 23

  22. Slide 22: Preclinical and Clinical Evidence of Efficacy

    Slide 22: Preclinical and Clinical Evidence of Efficacy

    Preclinical and Clinical Evidence of Efficacy 21 Animal Data • Betahistine attenuates olanzapine induced weight gain by counteracting increased expression of H 1 receptor, pAMPK, orexigenic neuropeptide Y and decreased expression of anorexigenic neuropeptide pro - opiomelanocortin 1 • No interferenc

  23. Slide 23: AM-201 Intranasal Betahistine for Mental Health Supportive Care

    Slide 23: AM-201 Intranasal Betahistine for Mental Health Supportive Care

    22 AM - 201 Intranasal Betahistine for Mental Health Supportive Care Target Indication: prevention of olanzapine - induced weight gain • Secondary: drowsiness, metabolic side effects • Same product as AM - 125, potential difference in dose – important development synergies Objective: get olanzapine’

  24. Slide 24: AM-201 Phase 1b Interim Data

    Slide 24: AM-201 Phase 1b Interim Data

    23 AM - 201 Phase 1b Interim Data • Interim analysis with 50 healthy volunteers » 10 subjects per dose (5M + 5F): 8 on active, 2 on placebo • Treatment well tolerated » Suited for longer term use • First efficacy signals – reduction in weight gain and daytime sleepiness » More pronounced changes in

  25. Slide 25: Attractive Market Opportunity in Mental Disorder Supportive Care

    Slide 25: Attractive Market Opportunity in Mental Disorder Supportive Care

    24 Attractive Market Opportunity in Mental Disorder Supportive Care ~2.2 million people diagnosed with schizophrenia ~3.6 million people diagnosed with bipolar disorder ~550,000 people treated with olanzapine >$0.6 billion estimated global market opportunity for AM - 201 Total number of patients in

  26. Slide 26: AM-201 Advisory Board

    Slide 26: AM-201 Advisory Board

    25 AM - 201 Advisory Board Christoph U. Correll, MD • Professor of Psychiatry and Molecular Medicine at The Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell in NY • Professor of Child and Adolescent Psychiatry, Charité Universitätsmedizin , Berlin , Germany John Kane, MD • Senior V

  27. Slide 27: Other Betahistine Opportunities

    Slide 27: Other Betahistine Opportunities

    26 Other Betahistine Opportunities www.aurismedical.com | NASDAQ: EARS Indication Background Prader - Willi Syndrome (PWS) Acquired U.S. Orphan Drug Designation for treatment of obesity associated with PWS. Rare genetic disorder characterized by progressive obesity, behavioral issues, delayed cognit

  28. Slide 28: Hearing Loss and Tinnitus Programs

    Slide 28: Hearing Loss and Tinnitus Programs

    Hearing Loss and Tinnitus Programs (Auris Medical Cochlear therapies Pa

  29. Slide 29: Sonsuvi (AM-111) for Acute Inner Ear Hearing Loss

    Slide 29: Sonsuvi (AM-111) for Acute Inner Ear Hearing Loss

    AM - 111 prevents or attenuates hearing loss by protecting hair cell functionality Sonsuvi ® (AM - 111) for Acute Inner Ear Hearing Loss 28 • Potent cell - penetrating JNK inhibitor peptide protecting against apoptosis and inflammation • C - jun N - terminal Kinase (JNK) involved in various cochlear

  30. Slide 30: Phase 3 Results Demonstrate Potential of Sonsuvi

    Slide 30: Phase 3 Results Demonstrate Potential of Sonsuvi

    Program to be developed through partnering (Process ongoing) 0 5 10 15 20 25 30 35 40 45 50 Day 3 Day 7 Day 28 Day 91 AM-111 0.4 mg/mL AM-111 0.8 mg/mL Placebo 29 Ph 3 Results Demonstrate Potential of Sonsuvi ® in Subpopulation with Profound Acute Hearing Loss Profound A cute H earing L oss (≥ 90 dB

  31. Slide 31: Keyzilen (AM-101) for Acute Inner Ear Tinnitus

    Slide 31: Keyzilen (AM-101) for Acute Inner Ear Tinnitus

    Keyzilen ® (AM - 101) for Acute Inner Ear Tinnitus • Keyzilen ® contains Esketamine hydrochloride, a potent N - Methyl - D - Aspartate (NMDA) receptor antagonist, formulated in a biodegradable gel » Targets aberrant excitation of the auditory nerve which is at the origin of certain types of tinnitus

  32. Slide 32: Advancing Keyzilen through Strategic Partnerships

    Slide 32: Advancing Keyzilen through Strategic Partnerships

    Advancing Keyzilen ® through Strategic Partnerships 31 • Phase 3 trials TACTT2 and TACTT3 trials did not meet primary efficacy endpoints • Issues with study design… » Switch from visit - based to daily ratings of tinnitus loudness as part of Special Protocol Assessment with FDA » Increased patient f

  33. Slide 33: IP, Financials and Outlook

    Slide 33: IP, Financials and Outlook

    IP, Financials and Outlook (Auris Medical Cochlear therapies 22

  34. Slide 34: Intellectual Property

    Slide 34: Intellectual Property

    33 Intellectual Property AM - 125 / AM - 201 • Composition of matter and methods of use for formulations of betahistine dihydrochloride for intranasal delivery (to 2038) • Up to 10 years of data protection in Europe • Acquired two US patents relevant to antipsychotic induced weight gain (to 2024) •

  35. Slide 35: First Half 2019 Financials

    Slide 35: First Half 2019 Financials

    34 First Half 2019 Financials www.aurismedical.com | NASDAQ: EARS Key figures in the Statement of Financial Position 2019 (Ended June 30) (CHF 1,000) 2018 (Ended Dec. 31) (CHF 1,000) Cash Balance 5,792 5,393 Shareholders’ Equity 8,952 3,650 Loan Facility - 1,435 CHF 4.8 CHF 3.6 CHF 0.0 CHF 1.0 CHF 2

  36. Slide 36: Upcoming Value-Creating Milestones

    Slide 36: Upcoming Value-Creating Milestones

    35 Upcoming Value - Creating Milestones Q1 2020 Interim data AM - 125 Phase 2 trial (Part A) Q1 2020 Data from Cohort 6 in AM - 201 Phase 1b trial Q2 2020 Start Part B of AM - 125 Phase 2 trial Q2 2020 IND www.aurismedical.com | NASDAQ: EARS

  37. Slide 37: Key Takeaways

    Slide 37: Key Takeaways

    36 Key Takeaways Large U.S. and global market opportunity No FDA approved products, great unmet medical need Low risk reformulation project with intranasal betahistine Existing market in vertigo Leveraging data for other indications Partnering potential with late - stage pipeline Several value creat

Source: SEC EDGAR · 6-K filed Oct 23, 2019

More decks from Altamira Therapeutics Ltd.

All 7 Altamira Therapeutics decks